REFERENCES
- Bleyer A W, Poplack D. Clinical studies on the central nervous system pharmacology of methotrexat. H., Pinedo. Clinical Pharmacology of Anti-Neoplastic Drugs. Amsterdam, Elsevier. 1978; 115–129
- Isacoff W H, Morrison P F, Aroesty J, et al, Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep.. 1977; 61: 1665–1674. [PUBMED], [INFOTRIEVE]
- Von Hoff D D, Penta J S, Helman L J, et al, Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep.. 1977; 61: 745–748. [PUBMED], [INFOTRIEVE]
- Hamel E, Johnson G, Glaubiger D. Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. Cancer Treat Rep.. 1981; 65: 545–553. [PUBMED], [INFOTRIEVE]
- Bleyer W A. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978; 41: 36–51. [PUBMED], [INFOTRIEVE]
- Jolivet J, Cowan K H, Curt G A, et al, The pharmacology and clinical use of methotrexate. N Engl J Med.. 1983; 309: 1094–1104. [PUBMED], [INFOTRIEVE]
- Treon S P, Chabner B A. Concepts in use of high-dose methotrexate therapy. Clin Chem.. 1996; 42: 1322–1329. [PUBMED], [INFOTRIEVE]
- Jonsson O G, Kamen B A. Methotrexate and childhood leukemia. Cancer Invest. 1991; 9: 53–60. [PUBMED], [INFOTRIEVE]
- Bick R L. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost. 1978; 5: 1–26. [PUBMED], [INFOTRIEVE]
- Nand S, Fisher S G, Salgia R, et al, Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol.. 1987; 5: 1998–2003. [PUBMED], [INFOTRIEVE]
- Nand S, Messmore H. Hemostasis in malignancy. Am J Hematol. 1990; 35: 45–55. [PUBMED], [INFOTRIEVE]
- Zaunschirm A, Muntean W. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol.. 1986; 3: 19–25. [PUBMED], [INFOTRIEVE]
- Vellenga E, Kluft C, Mulder N H, et al, The influence of L-asparaginase therapy on the fibrinolytic system. Br J Haematol. 1984; 57: 247–254. [PUBMED], [INFOTRIEVE]
- Troy K, Essex D, Rand J, et al, Protein C and S levels in acute leukemia. Am J Hematol. 1991; 37: 159–162. [PUBMED], [INFOTRIEVE]
- Pui C H, Boyett J M, Rivera G K, et al, Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia.. 2000; 14: 2286–2294. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Oner A F, Gurgey A, Kirazli S, et al, Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leuk Lymphoma. 1999; 33: 361–364. [PUBMED], [INFOTRIEVE]
- Homans A C, Rybak M E, Baglini R L, et al, Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol.. 1987; 5: 811–817. [PUBMED], [INFOTRIEVE]
- Feffer S E, Carmosino L S, Fox R L. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer. 1989; 1(63)1303–1307
- Totan M, Dagdemir A, Ak A R, et al, Effects of high-dose methotrexate on the hemostatic system in childhood acute lymphoblastic leukemia. Med Pediatr Oncol.. 2001; 36: 429–433. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Bowill E G, Tracy R P. Fibrin(ogen) degradation product. Boutler E, Lichtman M A. Williams Hematology, (Fifth Edition), New York, McGraw-Hill, Inc. 1995; L47
- Seligsohn U. Dissemine Intravascular Coagulatio. Boutler E, Lichtman M A. Williams Hematology, (Fifth Edition), New York, McGraw-Hill, Inc. 1995; 1497–1516